|
|
|
09.03.26 - 13:12
|
XFRA: XP0: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
XENON PHARMACEUTICALS XP0 CA98420N1050
AB/FROM ONWARDS 09.03.2026 12:53 CET...
|
|
|
09.03.26 - 12:57
|
XFRA: XP0: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
XENON PHARMACEUTICALS XP0 CA98420N1050 BAW/UFN...
|
|
|
|
|
09.03.26 - 12:06
|
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS). Azetukalner is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression....
|
|
|
08.03.26 - 19:03
|
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026....
|
|
|
|
|
16.01.26 - 22:09
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
12.01.26 - 14:33
|
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today outlined forward momentum across the Company's Phase 3 portfolio and discussed pipeline progress at the 2026 J.P. Morgan Healthcare Conference....
|
|
|
05.01.26 - 14:33
|
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026....
|
|
|
|
|
29.12.25 - 12:21
|
Xenon Pharmaceuticals Aktie: Rivale scheitert - Xenon profitiert? (Aktiencheck)
|
|
|
St. Louis (www.aktiencheck.de) - Xenon Pharmaceuticals-Aktienanalyse von Stifel:
Paul Matteis, Analyst von Stifel, habe das Rating "buy" für die Aktie von Xenon Pharmaceuticals Inc. (ISIN: CA98420N1050, WKN: A12ETN, Ticker-Symbol: XP0, NASDAQ-Symbol: XENE) beibehalten, nachdem Biohavens Kv7-Wirkstoff in einer Studie bei Major Depressive Disorder (MDD) gescheitert sei. [mehr]...
|
|
|
|
|
|
|
05.12.25 - 15:03
|
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS), multiple real world studies on the burden of depression and anti-seizure medication (ASM) titration in epilepsy, and new data for its pre-clinical program in Dravet syndrome. These data are being presented at the American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 in Atlanta, Georgia....
|
|
|
04.12.25 - 23:24
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of December 4, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
03.12.25 - 14:33
|
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the American Epilepsy Society Annual Meeting (AES 2025), including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in focal onset seizures (FOS) and real world study data on the impact of depression and burden of titration in epilepsy. The webinar will also include an update on the company's progress preparing for commercialization of azetukalner....
|
|
|
25.11.25 - 14:33
|
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 at the Georgia World Congress Center in Atlanta, Georgia. Seven posters will be presented, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS), and data characterizing patterns of seizure freedom epochs with extended use of azetukalner, which could inform future clinical practice. Xenon's poster presentations also include findings on the impact of depression on epilepsy patients, as well as new pre-clinical data from the Company's early-stage NaV1.1 program in Dravet syndrome....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
